Open Access

Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)

  • Authors:
    • Yunhong Yu
    • Peng Jiang
    • Pan Sun
    • Na Su
    • Fangzhao Lin
  • View Affiliations

  • Published online on: May 2, 2021     https://doi.org/10.3892/etm.2021.10125
  • Article Number: 693
  • Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Death receptor 3 (DR3) and its corresponding ligand, tumor necrosis factor‑like ligand 1A (TL1A), belong to the tumor necrosis factor superfamily. Signaling via this receptor‑ligand pair results in pro‑inflammatory and anti‑inflammatory effects. Effector lymphocytes can be activated to exert pro‑inflammatory activity by triggering the DR3/TL1A pathway. By contrast, DR3/TL1A signaling also induces expansion of the suppressive function of regulatory T cells, which serve an important role in exerting anti‑inflammatory functions and maintaining immune homeostasis. Preclinical evidence indicates that neutralizing and agonistic antibodies, as well as ligand‑based approaches targeting the DR3/TL1A pathway, may be used to treat diseases, including inflammatory and immune‑mediated diseases. Accumulating evidence has suggested that modulating the DR3/TL1A pathway is a promising therapeutic approach for patients with these diseases. This review discusses preclinical models to gauge the progress of therapeutic strategies for diseases involving the DR3/TL1A pathway to aid in drug development.
View Figures
View References

Related Articles

Journal Cover

July-2021
Volume 22 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yu Y, Jiang P, Sun P, Su N and Lin F: Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review). Exp Ther Med 22: 693, 2021
APA
Yu, Y., Jiang, P., Sun, P., Su, N., & Lin, F. (2021). Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review). Experimental and Therapeutic Medicine, 22, 693. https://doi.org/10.3892/etm.2021.10125
MLA
Yu, Y., Jiang, P., Sun, P., Su, N., Lin, F."Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)". Experimental and Therapeutic Medicine 22.1 (2021): 693.
Chicago
Yu, Y., Jiang, P., Sun, P., Su, N., Lin, F."Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)". Experimental and Therapeutic Medicine 22, no. 1 (2021): 693. https://doi.org/10.3892/etm.2021.10125